Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.1% – Here’s What Happened

Vor Biopharma Inc. (NASDAQ:VOR)’s stock price traded down 5.1% during mid-day trading on Monday . The company traded as low as $19.79 and last traded at $19.5450. Approximately 179,481 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 1,076,841 shares. The stock had previously closed at $20.59.

Analyst Upgrades and Downgrades

VOR has been the subject of a number of recent analyst reports. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Wells Fargo & Company initiated coverage on Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research note on Monday, May 18th. Wedbush lifted their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Vor Biopharma Trading Down 5.1%

The firm’s fifty day moving average price is $15.15 and its 200-day moving average price is $14.67.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. On average, equities research analysts forecast that Vor Biopharma Inc. will post -2.51 earnings per share for the current year.

Insider Buying and Selling

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 530,610 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $16.15, for a total value of $8,569,351.50. Following the completion of the sale, the director owned 3,404,998 shares in the company, valued at approximately $54,990,717.70. This trade represents a 13.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 2,153,646 shares of company stock valued at $34,896,602. Corporate insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Vor Biopharma during the fourth quarter worth $36,000. Goldman Sachs Group Inc. raised its stake in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Vor Biopharma during the 2nd quarter worth about $66,000. Chung Wu Investment Group LLC bought a new position in shares of Vor Biopharma during the 4th quarter worth about $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at about $134,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).